Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
Pertuzumab/trastuzumab/hyaluronidase-zzxf | Phesgo | HER2 (ERBB2) Antibody 76 | Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) is an injectable formulation consists of Perjeta (pertuzumab), Herceptin (trastuzumab), and hyaluronidase, which demonstrates anti-tumor activity against ERBB2 (HER2)-positive breast cancer (Cancer Res 2020;80(4 Suppl):Abstract nr PD4-07). Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf injection) is FDA approved for use in combination with chemotherapy in ERBB2 (HER2)-positive early breast cancer, and in combination with Taxotere (docetaxel) in ERBB2 (HER2)-positive metastatic breast cancer that has not received prior anti-HER2 therapy (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05256225 | Phase II | Carboplatin + Paclitaxel + Pertuzumab/trastuzumab/hyaluronidase-zzxf Carboplatin + Paclitaxel Carboplatin + Paclitaxel Trevatide + trastuzumab and hyaluronidase-oysk injection | Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Recruiting | USA | 1 |